Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea
Main finding · Incident OAResult — go to the resultAdjusted hazard ratio 0.76 95% CI 0.68–0.85Authors' conclusion
In this cohort study of individuals with diabetes, metformin treatment was associated with a significant reduction in the risk of developing OA compared with sulfonylurea treatment.
Study context
- Population
- Adults aged 40 years or older with type 2 diabetes and at least 1 year of continuous enrollment, without prior osteoarthritis (OA), inflammatory arthritis or joint replacement; Optum Clinformatics claims data, December 2003 to December 2019propensity-score matched
- Participants
- 20,937 vs 20,937
- Exposure
- Metformin vs a sulfonylurea in type 2 diabetes
- Metforminn = 20,937
- Sulfonylurean = 20,937reference
- Outcome
- Incident OA and joint replacement
Methodological detailstime-conditional propensity-score matched, prevalent new-user cohort, claims data, Cox proportional hazard models
- Time-conditional propensity-score matched
- Prevalent new-user cohort
- Claims data
- Cox proportional hazard models
Main finding
Incident OA
Adjusted hazard ratio
0.76
95% CI 0.68–0.85
P < 0.001
Metforminvs Sulfonylurea
aHR 0.76 (95% CI 0.68–0.85); P < 0.001
As reported in the abstract
Observational data: associations, not effects.
Further findings
| Outcome | aHR (95% CI) | P value | |
|---|---|---|---|
| Joint replacement | 0.80 (0.50–1.27) | P = 0.34 | |
| Incident OA, sensitivity analysis (only ever metformin vs only ever sulfonylurea)Sensitivity analysis | 0.77 (0.65–0.90) | P < 0.001 | |
| Joint replacement, sensitivity analysis (only ever metformin vs only ever sulfonylurea)Sensitivity analysis | 1.04 (0.60–1.82) | P = 0.89 | |
| 0.512Adjusted hazard ratio (log scale) |
Joint replacement
- No significant difference for risk of joint replacement
Original publication
Development of Osteoarthritis in Adults With Type 2 Diabetes Treated With Metformin vs a Sulfonylurea. JAMA Netw Open. Published 1 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →